-+ 0.00%
-+ 0.00%
-+ 0.00%

Puma Biotechnology publishes 2025 annual report

PUBT·04/28/2026 21:03:51
Listen to the news
Puma Biotechnology publishes 2025 annual report
  • Puma Biotechnology annual report for fiscal 2025 highlighted renewed US demand growth for NERLYNX, first year-over-year increase since 2018.
  • Company advanced alisertib program, with Phase II ALISCA-Breast1 enrolling faster than expected and setting interim data release in first half of 2026.
  • Phase II ALISCA-Lung1 trial in extensive-stage small cell lung cancer continued enrollment, with interim data also targeted for first half of 2026.
  • NERLYNX gained additional visibility in clinical practice guidelines during 2025, including listings for HER2-mutated metastatic breast cancer and cervical cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief on April 28, 2026, and is solely responsible for the information contained therein.